The landscape of diabetes care is evolving with the emergence of transdermal GLP-1 delivery . These novel patches offer a possibly more comfortable alternative to injections for individuals living with type 2 diabetes . Such a system deliver a GLP-1 agonist directly through the skin , avoiding the need for frequent injections and potentially improv